The fibrates which act as PPARα agonists, such as Fenofibrate and Gemfibrozil, improve some symptomatic aspects of NASH such as liver function, lipid profile and insulin sensitivity, but do not influence the histopathology and have numerous side effects (e.g., impaired kidney function, increase in serum creatinine and homocysteine) [117,118,119,120,121]. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.